This product is a lipid-regulating drug of the clofibric acid derivative class. Its mechanism of action in lowering blood lipids is not yet fully understood. It may involve peripheral fat decomposition, reduce the liver's uptake of free fatty acids and reduce the formation of triglycerides in the liver, inhibit the synthesis of very low-density lipoprotein apolipoproteins and reduce the production of very low-density lipoproteins. This product reduces blood triglycerides and increases blood high-density lipoprotein concentrations. Although it can slightly reduce blood low-density lipoprotein cholesterol blood concentrations, it may increase low-density lipoprotein in type IV hyperlipoproteinemia. A 5-year placebo-controlled study showed that this product can reduce the occurrence of severe coronary heart disease sudden death and myocardial infarction. Long-term administration of 10 times the human dose to rats increased the incidence of liver malignancies and benign testicular tumors.

Telmisartan is an orally effective, specific angiotensin II receptor (AT1 type) antagonist that binds to the angiotensin II receptor AT1 subtype with high affinity. The binding effect is long-lasting, but without any partial agonist effect. Telmisartan can cause a decrease in blood aldosterone levels, does not inhibit human plasma renin, does not block ion channels, does not affect bradykinin degradation, and has no affinity for other receptors. Telmisartan can reduce systolic and diastolic blood pressure in hypertensive patients without affecting heart rate, and has an antihypertensive effect comparable to other types of representative antihypertensive drugs.